Nova Patents
EP0605477B1

Gaseous ultrasound contrast media

Abstract

Disclosed herein are agents for enhancing the contrast in an ultrasound image. These agents are extremely small bubbles, or "microbubbles," comprised of specially selected gases. The microbubbles described herein exhibit long life spans in solution and may be produced at a size small enough to traverse the lungs, thus enabling improved ultrasound imaging of the cardiovascular system and other vital organs. Also disclosed herein is a method for selecting gases from which contrast agents may be produced. The method is based on calculations using inherent physical properties of gases and describes a means to associate the properties of a gas with the time for dissolution of microbubbles comprised of the gas.

EP0605477B1, drawing sheet 1
Sheet 1 of 15

Term

Term ended

Expired 2 September 2012, 14.1 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

10 claims: 8 independent, 2 dependent

  1. 1
    Contrast media for ultrasound image-enhancement comprising microbubbles of a biocompatible gas or a combination of gases in a biocompatible aqueous liquid vehicle, the gas or gases being selected from hexafluoropropylene, octafluoropropane, octafluoro-2-butene, hexafluoro-2-butyne, hexafluorobuta-1,3-diene, octafluorocyclobutane and decafluorobutane.
  2. 2
    Contrast media for ultrasound image-enhancement comprising microbubbles of a biocompatible gas or a combination of gases in a biocompatible aqueous liquid vehicle, the gas or gases comprising dodecafluoropentane.
  3. 4
    Contrast media according to any of claims 1 to 3 comprising an aqueous solution of sorbitol as viscosity enhancing agent.
  4. 5
    Contrast media according to any of claims 1 to 4 further comprising polyethoxy sorbitan laurate.
  5. 6
    Use of one or more of hexafluoropropylene, octafluoropropane, octafluoro-2-butene, hexafluoro-2-butyne, hexafluorobuta-1,3-diene, octafluorocyclobutane and decafluorobutane for the production of contrast-enhancing media for ultrasound imaging.
  6. 7
    Use of dodecafluoropentane for the production of contrast-enhancing media for ultrasound imaging.
  7. 8
    Use according to any of the claims 6 or 7 for the production of contrast media for the contrast-enhanced ultrasound diagnosis of the cardiovascular system.
  8. 9
    Use according to any of claims 6 to 8 for the production of contrast media for the ultrasound imaging of the left ventricle of the heart.
  9. 10
    Use according to any of claims 6 to 9 for the production of contrast-enhancing media for ultrasound imaging in the form of gas emulsions in a biocompatible aqueous liquid vehicle.